Virtual Challenging Case Clinic: B-Cell Lymphomas
- Delve into treatment paradigms, available therapies, and agents under development for various subtypes of B-cell lymphomas
- Expert insights on particularly challenging patient cases submitted by actual attendees

Course Director
John P. Leonard, MD
Senior Associate Dean for
Innovation and Initiatives
Executive Vice Chair,
Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York
Agenda
- Welcome, Introductions, and
Pre-session Survey - General Disease State and
Treatment Guidelines - Expert Insights: Faculty-submitted cases
- Case Presentation, Polling Questions,
and Discussion - Q&A
- Conclusion and Post-session Survey
Follicular Lymphoma
Jonathon Cohen, MD, MS
Winship Cancer Institute of Emory University | Atlanta, Georgia
Wednesday, December 9, 2020
Year in Review
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Wednesday, January 13, 2021
Marginal Zone Lymphoma
Peter Martin, MD
Weill Cornell Medicine | New York, New York
Broadcast on November 11, 2020
T-cell Lymphoma
Kerry Savage, MD
University of British Columbia | Vancouver, Canada
Broadcast on October 14, 2020
Hodgkin Lymphoma
Jonathan Friedberg, MD, MMSc
University of Rochester Medical Center | Rochester, New York
Broadcast on September 9, 2020
Updates from ASCO and EHA
John P. Leonard, MD
Weill Cornell Medical College | New York, New York
Broadcast on August 12, 2020
Chronic Lymphocytic Leukemia
Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on July 8, 2020
Transformed Lymphoma
Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on June 10, 2020
Diffuse Large B-cell Lymphoma
Mitchell Smith, MD, PhD
George Washington University | Washington, District of Columbia
Broadcast on May 13, 2020
CAR T-Cell Therapy
Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on April 8, 2020
Mantle Cell Lymphoma
Thomas Witzig, MD
Mayo Clinic | Rochester, Minnesota
Broadcast on March 11, 2020
Updates from ASH
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on February 19, 2020
Target Audience
Learning Objectives
- Assess best available evidence regarding treatment of indolent and aggressive B-cell lymphomas
- Evaluate the clinical implications of emerging data regarding B-cell lymphoma treatment approaches
- Plan strategies to address complicated B-cell lymphoma cases
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Disclosure Statement
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
Contact Us
Questions? Please contact Bio Ascend by phone: 888-476-9129 or email: info@bioascend.com!
This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.